NEW YORK, Feb. 16, 2018 /PRNewswire/ --
WallStEquities.com strives to bring the best free research to the investmentcommunity. Today we are offering reports on BDX, EKSO, COO, and WAT which can be accessed for free by signing up to www.wallstequities.com/registration. WallStEquities.com shifts focus on the Medical Instruments and Supplies industry, which primarily
On Thursday, shares in Franklin Lakes, New Jersey-based Becton, Dickinson and Co. recorded a trading volume of 981,876 shares. The stock ended at $222.51, rising 1.16% from the last trading session. The Company's shares have gained 23.55% in the last twelve months. The stock is trading above its 200-day moving average by 7.83%. Furthermore, shares of the Company, which develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide, have a Relative Strength Index (RSI) of 45.38.
On January 19th, 2018, research firm Bank of America/ Merrill resumed its 'Buy' rating on the Company's stock, with a target price of $260 per share. Get the full research report on BDX for free by clicking below at: www.wallstequities.com/registration/?symbol=BDX
Ekso Bionics Holdings
Richmond, California headquartered Ekso Bionics Holdings Inc.'s stock finished yesterday's session flat at $1.53. A total volume of 227,572 shares was traded. The stock is trading below its 50-day moving average by 21.68%. Furthermore, shares of Ekso Bionics, which designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America and EMEA region, have an RSI of 44.07. EKSO's complimentary research coverage is a few simple steps away at: www.wallstequities.com/registration/?symbol=EKSO
At the close of trading on Thursday, shares in Pleasanton, California headquartered The Cooper Cos. Inc. saw a rise of 1.19%, ending the day at $232.53. The stock recorded a trading volume of 263,567 shares. The Company's shares have advanced 21.55% over the last twelve months. The stock is trading above its 50-day moving average by 0.76%. Moreover, shares of Cooper Cos., which operates as a medical device company worldwide, have an RSI of 49.35. Register for your free research report on COO at: www.wallstequities.com/registration/?symbol=COO
Milford, Massachusetts-based Waters Corp.'s shares ended the day 1.11% higher at $206.90 with a total trading volume of 465,199 shares. The stock has gained 34.87% over the last twelve months. The Company's shares are trading above their 50-day and 200-day moving averages by 2.02% and 9.63%, respectively. Additionally, shares of Waters, which operates as an analytical instrument manufacturer in the US and internationally, have an RSI of 52.39.
On January 24th, 2018, research firm Janney reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $200 share to $230 a share. Wall St. Equities' downloadable research report on WAT available at: www.wallstequities.com/registration/?symbol=WAT
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: email@example.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/this-mornings-technical-outlook-on-medical-supplies-stocks----becton-dickinson-ekso-bionics-cooper-and-waters-300599986.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
FDA approved elapegademase-lvlr injection for intramuscular use is used as an enzyme replacement ...
Armpit lumps and raised bumps in the armpits caused by infection, cysts and other types of ...
Bad eating habits will affect your health as well as your skin and make you look older than your ...View All